1) Reese RE, Betts RF : Antibiotic use. In Betts RF, Chapman SW, Penn RL, eds : A practical approach to infectious diseases, 5 th ed, Lippincott Williams & Wilkins, Philadelphia, 2003, p969-1153.
2) Gilbert DN, Moellering RC Jr, Eliopoulos GM, Chambers HF, Saag MS : 日本語版サンフォード感染症治療ガイド 2011, 第41版, ライフサイエンス出版, 東京, 2011.
3) MacGowan AP : Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J Antimicrob Chemother 51 (Suppl 2) : ii17-ii25, 2003.
4) Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ : Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 42 : 1411-1423, 2003.
5) Kosmidis C, Levine DP : Daptomycin : pharmacology and clinical use. Expert Opin Pharmacother 11 : 615-625, 2010.
6) Edson RS, Terrell CL : The aminoglycosides. Mayo Clin Proc 74 : 519-528, 1999.
7) Vesely JJ, Pien FD, Pien BC : Rifampin, a useful drug for nonmycobacterial infections. Pharmacotherapy 18 : 345-357, 1998.
8) Cavalcanti AB, Goncalves AR, Almeida CS, Bugano DDG, Silva E : Teicoplanin versus vancomycin for proven or suspected infection (Review). Cochrane Database Syst Rev 6, 2010.
9) Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP : Vancomycin therapeutic guidelines : a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 49 : 325-327, 2009.
10) Sivagnanam S, Deleu D : Red man syndrome. Crit Care 7 : 119-120, 2003.
11) Vinh DC, Rubinstein E : Linezolid : a review of safety and tolerability. J Infect 59 (S1) : S59-S74, 2009.
12) Miller BA, Gray A, LeBlanc TW, Sexton DJ, Martin AR, Slama TG : Acute eosinophilic pneumonia secondary to daptomycin : a report of three cases. Clin Infect Dis 50 : e63-e68, 2010.
13) Xing G, Chen Z, Cao X : Mitochondrial rRNA and tRNA and hearing function. Cell Res 17 : 227-239, 2007.
14) Healy DP, Sahai JV, Fuller SH, Polk RE : Vancomycin- induced histamine release and "red man syndrome" : comparison of 1- and 2-hour infusions. Antimicrob Agents Chemother 34 : 550-554, 1990.
15) Rubinstein E, Isturiz R, Standiford HC, Smith LG, Oliphant TH, Cammarata S, Hafkin B, Le V, Remington J : Worldwide assessment of linezolid's clinical safety and tolerability : comparator- controlled phase III studies. Antimicrob Agents Chemother 47 : 1824-1831, 2003.
16) Toh SM, Xiong L, Arias CA, Villegas MV, Lolans K, Quinn J, Mankin AS : Acquisition of a natural resistance gene renders a clinical strain of methicillin- resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol 64 : 1506-1514, 2007.
17) Meka VG, Gold HS : Antimicrobial resistance to linezolid. Clin Infect Dis 39 : 1010-1015, 2004.
18) Farrell DJ, Mendes RE, Ross JE, Jones RN : Linezolid surveillance program results for 2008 (LEADER Program for 2008). Diagn Microbiol Infect Dis 65 : 392-403, 2009.
19) Sader HS, Jones RN : Antimicrobial susceptibility of Gram- positive bacteria isolated from US medical centers : results of the Daptomycin Surveillance Program (2007-2008). Diagn Microbiol Infect Dis 65 : 158-162, 2009.
20) Sader HS, Moet GJ, Farrell DJ, Jones RN : Antimicrobial susceptibility of daptomycin and comparator agents tested against methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci : trend analysis of a 6-year period in US medical centers (2005-2010). Diagn Microbiol Infect Dis 70 : 412-416, 2011.
21) Boucher HW, Sakoulas G : Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis 45 : 601-608, 2007.
22) Patel JB, Gorwitz RJ, Jernigan JA : Mupirocin resistance. Clin Infect Dis 49 : 935-941, 2009.
23) Logman JF, Stephens J, Heeg B, Haider S, Cappelleri J, Nathwani D, Tice A, van Hout BA : Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections. Curr Med Res Opin 26 : 1565-1578, 2010.
24) Shorr AF, Kunkel MJ, Kollef M : Linezolid versus vancomycin for Staphylococcus aureus bacteraemia : pooled analysis of randomized studies. J Antimicrob Chemother 56 : 923-929, 2005.
25) Stryjewski ME, Szczech LA, Benjamin DK Jr, Inrig JK, Kanafani ZA, Engemann JJ, Chu VH, Joyce MJ, Reller LB, Corey GR, Fowler VG Jr : Use of vancomycin or first-generation cephalosporins for the treatment of hemodialysis-dependent patients with methicillin-susceptible Staphylococcus aureus bacteremia. Clin Infect Dis 44 : 190-196, 2007.
26) Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF ; Infectious Diseases Society of America : Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52 : e18-e55, 2011.
27) Owens RC Jr, Lamp KC, Friedrich LV, Russo R : Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin. Am J Med 120 (Suppl 1) : S6-S12, 2007.
28) Ardura MI, Mejias A, Katz KS, Revell P, McCracken GH Jr, Sanchez PJ : Daptomycin therapy for invasive Gram- positive bacterial infections in children. Pediatr Infect Dis J 26 : 1128-1132, 2007.
29) Pelaez T, Alonso R, Perez C, Alcala L, Cuevas O, Bouza E : In vitro activity of linezolid against Clostridium difficile. Antimicrob Agents Chemother 46 : 1617-1618, 2002.
30) Leffler DA, Lamont JT : Treatment of Clostridium difficile-associated disease. Gastroenterology 136 : 1899-1912, 2009.
31) Stevens V, Dumyati G, Fine LS, Fisher SG, van Wijngaarden E : Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 53 : 42-48, 2011.
32) Bratzler DW, Houck PM : Surgical Infection Prevention Guideline Writers Workgroup : Antimicrobial prophylaxis for surgery : an advisory statement from the National Surgical Infection Prevention Project. Am J Surg 189 : 395-404, 2005.
33) Ammerlaan HS, Kluytmans JA, Wertheim HF, Nouwen JL, Bonten MJ : Eradication of methicillin-resistant Staphylococcus aureus carriage : a systematic review. Clin Infect Dis 48 : 922-930, 2009.
34) Wertheim HF, Verveer J, Boelens HA, van Belkum A, Verbrugh HA, Vos MC : Effect of mupirocin treatment on nasal, pharyngeal, and peritoneal carriage of Staphylococcus aureus in health adults. Antimicrob Agents Chemother 49 : 1465-1467, 2005.
35) Siegel JD, Rhinehart E, Jackson M, Chiarello L, the Healthcare Infection Control Practices Advisory Committee : Management of multidrug-resistant organisms in healthcare settings, 2006. Am J Infect Control 35 (Suppl 2) : S165-S193, 2007.
36) Sanchez Garcia M, De la Torre MA, Morales G, Pelaez B, Tolon MJ, Domingo S, Candel FJ, Andrade R, Arribi A, Garcia N, Martinez Sagasti F, Fereres J, Picazo J : Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit. JAMA 303 : 2260-2264, 2010.
37) Burns K, Morris-Downes M, Fawley WN, Smyth E, Wilcox MH, Fitzpatrick F : Infection due to C. difficile ribotype 078 : first report of cases in the Republic of Ireland. J Hosp Infect 75 : 287-291, 2010.